Medicamen Biotech Allots 5 Lakh Equity Shares to Promoter Group

Aggregate Consideration: Rs 26.50 Crore
New Paid-up Equity Share Capital: Rs 14,06,28,150

Reader Takeaway: Promoter entity Shivalik Rasayan boosts stake via warrant conversion, providing fresh capital infusion for Medicamen Biotech.

What just happened

Medicamen Biotech Limited has successfully completed the allotment of 5,00,000 equity shares following the conversion of fully convertible warrants. The allotment was approved by the company's Preferential Issue Committee on October 23, 2026. These shares were issued to Shivalik Rasayan Limited, a firm falling under the promoter and promoter group category.

Why this matters

The transaction results in a fresh cash infusion of Rs 26.50 crore for the company. By converting warrants into equity, the promoter group has increased its stake in the firm. This move is typically viewed by investors as a sign of confidence from the promoters in the long-term prospects of the business, while also strengthening the company's balance sheet.

Share Capital Adjustment

Post-allotment, the company’s paid-up equity share capital has increased to Rs 14,06,28,150. This represents a total of 14,062,815 equity shares with a face value of Rs 10 each. The process was conducted in full compliance with SEBI Listing Obligations and Disclosure Requirements regulations.

What to track next

Investors should monitor the company's subsequent quarterly filings to see how this capital is deployed toward operational growth or debt reduction. Additionally, the change in shareholding pattern will be reflected in upcoming regulatory disclosures.